{"pmid":32387581,"title":"Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic.","text":["Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic.","J Thorac Oncol","Chang, Hsu-Liang","Chen, Yen-Hsu","Yang, Chih-Jen","32387581"],"journal":"J Thorac Oncol","authors":["Chang, Hsu-Liang","Chen, Yen-Hsu","Yang, Chih-Jen"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387581","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jtho.2020.04.029","keywords":["covid-19","egfr tki","ild"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892760506369,"score":9.490897,"similar":[{"pmid":32383276,"title":"Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.","text":["Chronic myeloid leukemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.","Br J Clin Pharmacol","Eskazan, Ahmet Emre","32383276"],"journal":"Br J Clin Pharmacol","authors":["Eskazan, Ahmet Emre"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383276","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bcp.14353","keywords":["covid-19","chronic myeloid leukemia","qtc prolongation","sars-cov-2","drug-drug interaction","tyrosine kinase inhibitor"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666419683325116416,"score":72.86223},{"pmid":32503877,"title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","text":["Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.","Sci Immunol","Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H","32503877"],"abstract":["Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial."],"journal":"Sci Immunol","authors":["Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503877","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1126/sciimmunol.abd0110","locations":["Bruton"],"e_drugs":["acalabrutinib"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488360787968,"score":68.5253},{"pmid":32198915,"title":"[When COVID-19 encounters interstitial lung disease: challenges and management].","text":["[When COVID-19 encounters interstitial lung disease: challenges and management].","In December 2019, a new type of coronavirus pneumonia (COVID-19) emerged in Wuhan, Hubei, and spread rapidly to China and over 100 countries around the world. The lung injury and repair caused by COVID-19 has many similarities with the onset and progression of interstitial lung disease (ILD) . Therefore, it is difficult to distinguish between COVID-19 and some types of new-onset ILD or other causes leading to acute exacerbation of ILD. Clinicians need to comprehensively analyze the epidemic history, disease onset characteristics, clinical manifestations, image characteristics, serological andpathogenic microorganism test results to confirm diagnosis. Because of this, the article will discuss the issues related to the differential diagnosis and management of COVID-19 and ILD, and try to provide reasonable suggestions.","Zhonghua Jie He He Hu Xi Za Zhi","Ren, Y H","Wang, S Y","Liu, M","Guo, Y M","Dai, H P","32198915"],"abstract":["In December 2019, a new type of coronavirus pneumonia (COVID-19) emerged in Wuhan, Hubei, and spread rapidly to China and over 100 countries around the world. The lung injury and repair caused by COVID-19 has many similarities with the onset and progression of interstitial lung disease (ILD) . Therefore, it is difficult to distinguish between COVID-19 and some types of new-onset ILD or other causes leading to acute exacerbation of ILD. Clinicians need to comprehensively analyze the epidemic history, disease onset characteristics, clinical manifestations, image characteristics, serological andpathogenic microorganism test results to confirm diagnosis. Because of this, the article will discuss the issues related to the differential diagnosis and management of COVID-19 and ILD, and try to provide reasonable suggestions."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Ren, Y H","Wang, S Y","Liu, M","Guo, Y M","Dai, H P"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198915","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn112147-20200315-00339","keywords":["covid-19","differential diagnosis","interstitial lung disease"],"locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490085048321,"score":58.87375},{"pmid":32399097,"pmcid":"PMC7212214","title":"Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.","text":["Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.","Arch Med Sci","Nabavi, Seyed Fazel","Habtemariam, Solomon","Clementi, Emilio","Berindan-Neagoe, Ioana","Cismaru, Cosmin Andrei","Rasekhian, Mahsa","Banach, Maciej","Izadi, Morteza","Bagheri, Mahdi","Bagheri, Mohammad Sadegh","Nabavi, Seyed Mohammad","32399097"],"journal":"Arch Med Sci","authors":["Nabavi, Seyed Fazel","Habtemariam, Solomon","Clementi, Emilio","Berindan-Neagoe, Ioana","Cismaru, Cosmin Andrei","Rasekhian, Mahsa","Banach, Maciej","Izadi, Morteza","Bagheri, Mahdi","Bagheri, Mohammad Sadegh","Nabavi, Seyed Mohammad"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399097","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.5114/aoms.2020.94504","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666714494870487040,"score":53.612568},{"pmid":32436460,"title":"TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.","text":["TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.","Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFalpha, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses. The reviews of this paper are available via the supplemental material section.","Ther Adv Respir Dis","Chen, Xue-Yan","Yan, Bing-Xi","Man, Xiao-Yong","32436460"],"abstract":["Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFalpha, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses. The reviews of this paper are available via the supplemental material section."],"journal":"Ther Adv Respir Dis","authors":["Chen, Xue-Yan","Yan, Bing-Xi","Man, Xiao-Yong"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436460","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1753466620926800","keywords":["covid-19","tnfalpha inhibitor","etanercept","toxic epidermal necrolysis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393816764416,"score":48.437782}]}